These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

334 related items for PubMed ID: 28784002

  • 1. Secukinumab is the most efficient treatment for achieving clear skin in psoriatic patients: a cost-consequence study from the Spanish National Health Service.
    Puig L, Notario J, Jiménez-Morales A, Moreno-Ramírez D, López-Ferrer A, Gozalbo I, Prades M, Lizán L, Blanch C.
    J Dermatolog Treat; 2017 Nov; 28(7):623-630. PubMed ID: 28784002
    [Abstract] [Full Text] [Related]

  • 2. Cost-effectiveness of secukinumab as first biologic treatment, compared with other biologics, for moderate to severe psoriasis in Germany.
    Augustin M, McBride D, Gilloteau I, O'Neill C, Neidhardt K, Graham CN.
    J Eur Acad Dermatol Venereol; 2018 Dec; 32(12):2191-2199. PubMed ID: 29729105
    [Abstract] [Full Text] [Related]

  • 3. Number needed to treat and costs per responder among biologic treatments for moderate-to-severe plaque psoriasis in Japan.
    Imafuku S, Nakano A, Dakeshita H, Li J, Betts KA, Guerin A.
    J Dermatolog Treat; 2018 Feb; 29(1):24-31. PubMed ID: 28608740
    [Abstract] [Full Text] [Related]

  • 4. A Cost-per-Number Needed to Treat Analysis Assessing the Efficiency of Biologic Drugs in Moderate to Severe Plaque Psoriasis.
    Núñez M, Huete T, de la Cueva P, Sacristán JA, Hartz S, Dilla T.
    Actas Dermosifiliogr (Engl Ed); 2019 Sep; 110(7):546-553. PubMed ID: 30851873
    [Abstract] [Full Text] [Related]

  • 5. Cost per additional responder for ixekizumab and other FDA-approved biologics in moderate-to-severe plaque psoriasis.
    Al Sawah S, Foster SA, Burge R, Amato D, Schacht A, Zhu B, Hartz S, Leonardi C.
    J Med Econ; 2017 Dec; 20(12):1224-1230. PubMed ID: 28760056
    [Abstract] [Full Text] [Related]

  • 6. Ixekizumab for Treating Moderate-to-Severe Plaque Psoriasis: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
    Ramaekers BLT, Wolff RF, Pouwels X, Oosterhoff M, Van Giessen A, Worthy G, Noake C, Armstrong N, Kleijnen J, Joore MA.
    Pharmacoeconomics; 2018 Aug; 36(8):917-927. PubMed ID: 29480455
    [Abstract] [Full Text] [Related]

  • 7. Cost-effectiveness analysis of sequential biologic therapy with ixekizumab versus secukinumab as first-line treatment of moderate-to-severe psoriasis in the UK.
    Johansson EC, Hartz S, Kiri SH, Kumar G, Svedbom A.
    J Med Econ; 2018 Aug; 21(8):810-820. PubMed ID: 29873270
    [Abstract] [Full Text] [Related]

  • 8. Comparison of the cost-effectiveness of biologic drugs used for moderate-to-severe psoriasis treatment in the United States.
    Wu JJ, Feldman SR, Rastogi S, Menges B, Lingohr-Smith M, Lin J.
    J Dermatolog Treat; 2018 Dec; 29(8):769-774. PubMed ID: 29658383
    [Abstract] [Full Text] [Related]

  • 9. Dose Modification in Biologic Therapy for Moderate to Severe Psoriasis: A Descriptive Analysis in a Clinical Practice Setting.
    Baniandrés O, Rodríguez-Soria VJ, Romero-Jiménez RM, Suárez R.
    Actas Dermosifiliogr; 2015 Sep; 106(7):569-77. PubMed ID: 25935194
    [Abstract] [Full Text] [Related]

  • 10. Number needed to treat and costs per responder among biologic treatments for moderate-to-severe psoriasis: a network meta-analysis.
    Armstrong AW, Betts KA, Signorovitch JE, Sundaram M, Li J, Ganguli AX, Wu EQ.
    Curr Med Res Opin; 2018 Jul; 34(7):1325-1333. PubMed ID: 29619856
    [Abstract] [Full Text] [Related]

  • 11. Cost of biologics per treated patient across immune-mediated inflammatory disease indications in a pharmacy benefit management setting: a retrospective cohort study.
    Wu N, Lee YC, Shah N, Harrison DJ.
    Clin Ther; 2014 Aug 01; 36(8):1231-41, 1241.e1-3. PubMed ID: 25062652
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Cost-effectiveness analysis of secukinumab for the treatment of active psoriatic arthritis: a Canadian perspective.
    Goeree R, Chiva-Razavi S, Gunda P, Graham CN, Miles L, Nikoglou E, Jugl SM, Gladman DD.
    J Med Econ; 2018 Feb 01; 21(2):163-173. PubMed ID: 28945143
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Clinical and economic review of secukinumab for moderate-to-severe plaque psoriasis.
    Wong IT, Shojania K, Dutz J, Tsao NW.
    Expert Rev Pharmacoecon Outcomes Res; 2016 Feb 01; 16(2):153-66. PubMed ID: 26681527
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.